Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer

Isamu Okamoto, Kazuhiko Fujii, Mitsuhiro Matsumoto, Yasuhiro Terasaki, Nanae Kihara, Hirotsugu Kohrogi, Moritaka Suga

Research output: Contribution to journalArticlepeer-review

58 Citations (Scopus)


ZD1839 is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). We now present a case of diffuse alveolar damage (DAD) that developed in a 67-year-old man treated with ZD1839. On day 8 of ZD1839 administration, the patient complained of dyspnea and a new-ground glass opacity was apparent on a chest X-ray and computed tomography scan. Despite high-dose steroid therapy, the patient died 13 days after the first administration of ZD1839. Postmortem analysis of lung tissue revealed a pattern of DAD. No evidence of infection or of other specific etiologies was apparent. This case is the first reported of respiratory failure after ZD1839 treatment in a patient with NSCLC. Physicians should therefore be aware of the potential pulmonary toxicity of ZD1839.

Original languageEnglish
Pages (from-to)339-342
Number of pages4
JournalLung Cancer
Issue number3
Publication statusPublished - Jun 1 2003
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this